Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

被引：0
|
作者：
Hiroshi Yokouchi
Koichi Yamazaki
Ichiro Kinoshita
Jun Konishi
Hajime Asahina
Noriaki Sukoh
Masao Harada
Kenji Akie
Shigeaki Ogura
Takashi Ishida
Mitsuru Munakata
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura
机构：
[1] Hokkaido University School of Medicine,First Department of Medicine
[2] Hokkaido University Graduate School of Medicine,Department of Medical Oncology
[3] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine
[4] Sapporo City General Hospital,Department of Respiratory Disease
[5] Fukushima Medical University,Department of Pulmonary Medicine
[6] KKR Sapporo Medical Center,Department of Medical Oncology
[7] Hokkaido Lung Cancer Clinical Research Group,undefined
来源：
BMC Cancer | / 7卷
关键词：
Overall Survival; Epidermal Growth Factor Receptor; Bone Metastasis; Gefitinib; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib
    Koizumi, Tomonobu
    Agatsuma, Toshihiko
    Ikegami, Kayoko
    Suzuki, Toshiro
    Kobayashi, Takashi
    Kanda, Shintaro
    Yoshikawa, Sumiko
    Kubo, Keishi
    Shiina, Takayuki
    Takasuna, Keiichirou
    Matsuo, Akemi
    Hayasaka, Muneharu
    Morikawa, Miwa
    Ameshima, Shingo
    CLINICAL LUNG CANCER, 2012, 13 (06) : 458 - 463
  • [32] Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin
    Armour, Alison
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2007, 3 (02) : 66 - 78
  • [33] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
    Vasile, Enrico
    Tibaldi, Carmelo
    Chella, Antonio
    Falcone, Alfredo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 912 - 914
  • [34] Gefitinib first or gefitinib second -: Is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jaenne, Pasi A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (08) : 783 - 785
  • [35] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
  • [36] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    Horiike, A.
    Kudo, K.
    Miyauchi, E.
    Ohyanagi, F.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1131 - 1136
  • [37] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    A Horiike
    K Kudo
    E Miyauchi
    F Ohyanagi
    K Kasahara
    T Horai
    M Nishio
    British Journal of Cancer, 2011, 105 : 1131 - 1136
  • [38] Correlation of gefitinib and its metabolites with gefitinib induced rash in patients with non-small cell lung cancer (NSCLC).
    Guan, Shaoxing
    Chen, Xi
    Huang, Min
    Zhang, Li
    Wang, Xueding
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer
    Hoshi, Manabu
    Takami, Masatsugu
    Ieguchi, Makoto
    Takaoka, Kunio
    EUROPEAN JOURNAL OF ORTHOPAEDIC SURGERY AND TRAUMATOLOGY, 2009, 19 (03): : 181 - 185
  • [40] Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Velcheti, Vamsidhar
    Morgensztern, Daniel
    Govindan, Ramaswamy
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 83 - 90
12345